Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro model

References

• 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011).
  MedlineGoogle Scholar
• 2 Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr. Opin. Genet. Dev. 19(1), 67–73 (2009).
  MedlineGoogle Scholar
• 3 Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 130(4), 601–610 (2007).
  Medline CASGoogle Scholar
• 4 Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 432(7015), 332–337 (2004).
  Medline CASGoogle Scholar
• 5 Rhee S, Grinnell F. Fibroblast mechanics in 3D collagen matrices. Adv. Drug Deliv. Rev. 59(13), 1299–1305 (2007).
  Medline CASGoogle Scholar
• 6 Halliwell B. Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett. 540(1–3), 3–6 (2003).
  Medline CASGoogle Scholar
• 7 Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9(11), 4227–4239 (2003).
  MedlineGoogle Scholar
• 8 Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5(9), 741–754 (2006).
  Medline CASGoogle Scholar
• 9 Magdeldin T, Lopez-Davila V, Villemant C et al. The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer. J. Tissue Eng. 5, 2041731414544183 (2014).
  MedlineGoogle Scholar
• 10 Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99(19), 1441–1454 (2007).
  Medline CASGoogle Scholar
• 11 Mikhail AS, Eetezadi S, Allen C. Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: a comparison of docetaxel-loaded block copolymer micelles and Taxotere(R). PLoS ONE 8(4), e62630 (2013).
  Medline CASGoogle Scholar
• 12 Hickman JA, Graeser R, De Hoogt R et al. Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol. J. 9(9), 1115–1128 (2014).
  Medline CASGoogle Scholar
• 13 Huang K, Ma H, Liu J et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano 6(5), 4483–4493 (2012).
  Medline CASGoogle Scholar
• 14 Kunz-Schughart LA, Kreutz M, Knuechel R. Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int. J. Exp. Pathol. 79(1), 1–23 (1998).
  Medline CASGoogle Scholar
• 15 Holliday DL, Brouilette KT, Markert A, Gordon LA, Jones JL. Novel multicellular organotypic models of normal and malignant breast: tools for dissecting the role of the microenvironment in breast cancer progression. Breast Cancer Res. 11(1), R3 (2009).
  MedlineGoogle Scholar
• 16 Suri S, Schmidt CE. Cell-laden hydrogel constructs of hyaluronic acid, collagen, and laminin for neural tissue engineering. Tissue Eng. A 16(5), 1703–1716 (2010).
  Medline CASGoogle Scholar
• 17 Gurski LA, Jha AK, Zhang C, Jia X, Farach-Carson MC. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 30(30), 6076–6085 (2009).
  Medline CASGoogle Scholar
• 18 Christopher S, Szot CFB, Paul Gatenholm, Marissa Nichole Rylander, Freeman Joseph W. Investigation of cancer cell behavior on nanofibrous scaffolds. Mater. Sci. Eng. C 31(1), 37–42 (2011).
  Google Scholar
• 19 Ricketts Kate PM, Umber Cheema, Agata Nyga et al. A 3D In vitro cancer model as a platform for nanoparticle uptake and imaging investigations. Small 10(19), 3954–3961 (2014).
  Medline CASGoogle Scholar
• 20 Nyga A, Loizidou M, Emberton M, Cheema U. A novel tissue engineered three-dimensional in vitro colorectal cancer model. Acta Biomater. 9(8), 7917–7926 (2013).
  Medline CASGoogle Scholar
• 21 Lopez-Davila V, Seifalian AM, Loizidou M. Organic nanocarriers for cancer drug delivery. Curr. Opin. Pharmacol. 12(4), 414–419 (2012).
  Medline CASGoogle Scholar
• 22 Hino M, Ichihara H, Matsumoto Y, Ueoka R. Anti-tumor effects of cationic hybrid liposomes against colon carcinoma along with apoptosis in vitro. Biol. Pharm. Bull. 35(11), 2097–2101 (2012).
  Medline CASGoogle Scholar
• 23 Erdog A, Putra Limasale YD, Keskin D, Tezcaner A, Banerjee S. In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines. J. Pharm. Sci. 102(10), 3666–3677 (2013).
  Medline CASGoogle Scholar
• 24 Casado A, Sagrista ML, Mora M. Formulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecan. J. Pharm. Sci. 103(10), 3127–3138 (2014).
  Medline CASGoogle Scholar
• 25 Guo S, Huang L. Nanoparticles containing insoluble drug for cancer therapy. Biotechnol. Adv. 32(4), 778–788 (2014).
  Medline CASGoogle Scholar
• 26 Zhang Y, Li H, Sun J et al. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int. J. Pharm. 390(2), 198–207 (2010).
  Medline CASGoogle Scholar
• 27 Yang S, Chen J, Zhao D, Han D, Chen X. Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation efficiency. Int. J. Pharm. 434(1–2), 155–160 (2012).
  Medline CASGoogle Scholar
• 28 Ciani L, Ristori S, Salvati A, Calamai L, Martini G. DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery: zeta potential measurements and electron spin resonance spectra. Biochim. Biophys. Acta 1664(1), 70–79 (2004).
  Medline CASGoogle Scholar
• 29 Qu X, Khutoryanskiy VV, Stewart A et al. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. Biomacromolecules 7(12), 3452–3459 (2006).
  Medline CASGoogle Scholar
• 30 Siew A, Le H, Thiovolet M, Gellert P, Schatzlein A, Uchegbu I. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol. Pharm. 9(1), 14–28 (2012).
  Medline CASGoogle Scholar
• 31 Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schatzlein AG, Uchegbu IF. Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol. Pharm. 9(6), 1764–1774 (2012).
  Medline CASGoogle Scholar
• 32 Pelaz B, Charron G, Pfeiffer C et al. Interfacing engineered nanoparticles with biological systems: anticipating adverse nano-bio interactions. Small 9(9–10), 1573–1584 (2013).
  Medline CASGoogle Scholar
• 33 Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res. 17(5), 521–525 (2000).
  Medline CASGoogle Scholar
• 34 Lee WL, Guo WM, Ho VH et al. Inhibition of 3-D tumor spheroids by timed-released hydrophilic and hydrophobic drugs from multilayered polymeric microparticles. Small 10(19), 3986–3996 (2014).
  Medline CASGoogle Scholar
• 35 Oishi M, Nagasaki Y, Nishiyama N et al. Enhanced growth inhibition of hepatic multicellular tumor spheroids by lactosylated poly(ethylene glycol)-siRNA conjugate formulated in PEGylated polyplexes. ChemMedChem 2(9), 1290–1297 (2007).
  Medline CASGoogle Scholar
• 36 Perche F, Patel NR, Torchilin VP. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J. Control. Release 164(1), 95–102 (2012).
  Medline CASGoogle Scholar
• 37 Mozafari MR. Nanoliposomes: preparation and analysis. Methods Mol. Biol. 605, 29–50 (2010).
  Medline CASGoogle Scholar
• 38 RA Brown MW, Chuo CB, Cheema U, Nazhat SN. Ultrarapid engineering of biomimetic materials and tissues: fneabrication of nano- and microstructures by plastic compression. Adv. Funct. Mater. 15(11), 1762–1770 (2005).
  Google Scholar
• 39 Ciombor KK, Bekaii-Saab T. Selumetinib for the treatment of cancer. Expert Opin. Invest. Drugs 24(1), 111–123 (2015).
  Medline CASGoogle Scholar
• 40 Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc. Natl Acad. Sci. USA 106(19), 7957–7961 (2009).
  Medline CASGoogle Scholar
• 41 Kang SH, Cho HJ, Shim G et al. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm. Res. 28(12), 3069–3078 (2011).
  Medline CASGoogle Scholar
• 42 Lin J, Zhang H, Chen Z, Zheng Y. Penetration of lipid membranes by gold nanoparticles: insights into cellular uptake, cytotoxicity, and their relationship. ACS Nano 4(9), 5421–5429 (2010).
  Medline CASGoogle Scholar
• 43 Pisani M, Mobbili G, Paolo Bruni. Neutral Liposomes and DNA transfection. In: Non-Viral Gene Therapy. Yuan X-B (Ed.). Intech, Rijeka, Croatia (2011).
  Google Scholar
• 44 Ichihara H, Hino M, Umebayashi M, Matsumoto Y, Ueoka R. Intravenous injection of hybrid liposomes suppresses the liver metastases in xenograft mouse models of colorectal cancer in vivo. Eur. J. Med. Chem. 57, 143–148 (2012).
  Medline CASGoogle Scholar
• 45 Murrell MP, Voituriez R, Joanny JF, Nassoy P, Sykes C, Gardel ML. Liposome adhesion generates traction stress. Nat. Phys. 10(2), 163–169 (2014).
  CASGoogle Scholar
• 46 Shah V, Taratula O, Garbuzenko OB et al. Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Curr. Drug Discov. Technol. 10(1), 8–15 (2013).
  Medline CASGoogle Scholar
• 47 Andar AU, Hood RR, Vreeland WN, Devoe DL, Swaan PW. Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms. Pharm. Res. 31(2), 401–413 (2014).
  Medline CASGoogle Scholar
• 48 Polo ML, Arnoni MV, Riggio M, Wargon V, Lanari C, Novaro V. Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PLoS ONE 5(5), e10786 (2010).
  MedlineGoogle Scholar
• 49 Caputo E, Miceli R, Motti ML et al. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J. Transl. Med. 12, 216 (2014).
  MedlineGoogle Scholar
• 50 Ferguson J, Arozarena I, Ehrhardt M, Wellbrock C. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene 32(1), 86–96 (2013).
  Medline CASGoogle Scholar
• 51 Chambers KF, Mosaad EM, Russell PJ, Clements JA, Doran MR. 3D Cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared with cells cultured in monolayer. PLoS ONE 9(11), e111029 (2014).
  MedlineGoogle Scholar
• 52 Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat. Rev. Cancer 6(8), 583–592 (2006).
  Medline CASGoogle Scholar
• 53 Xiang X, Phung Y, Feng M et al. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS ONE 6(1), e14640 (2011).
  Medline CASGoogle Scholar